{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:44:22Z","timestamp":1791927862963,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.semnephrol.2026.151692","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:39:32Z","timestamp":1772109572000},"page":"151692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies"],"prefix":"10.1016","volume":"46","author":[{"given":"Maarten W.","family":"Taal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semnephrol.2026.151692_bib0001","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1523-1755.2003.t01-2-00052.x","article-title":"Retarding the progression of renal disease","volume":"64","author":"Brenner","year":"2003","journal-title":"Kidney Int"},{"issue":"16","key":"10.1016\/j.semnephrol.2026.151692_bib0002","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.semnephrol.2026.151692_bib0003","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJM198209093071104","article-title":"Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease","volume":"307","author":"Brenner","year":"1982","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151692_bib0004","first-page":"F85","article-title":"Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation","volume":"241","author":"Hostetter","year":"1981","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151692_bib0005","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151692_bib0006","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2026.151692_bib0007","series-title":"Brenner and Rector\u2019s The Kidney","first-page":"1470","article-title":"Mechanisms of progression in chronic kidney disease","author":"Taal","year":"2026"},{"key":"10.1016\/j.semnephrol.2026.151692_bib0008","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","article-title":"Pathophysiology of progressive nephropathies","volume":"339","author":"Remuzzi","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151692_bib0009","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151692_bib0010","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1523-1755.1998.00079.x","article-title":"The tubulointerstitium in progressive renal disease","volume":"54","author":"Nath","year":"1998","journal-title":"Kidney Int"},{"issue":"16","key":"10.1016\/j.semnephrol.2026.151692_bib0011","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1042\/CS20201016","article-title":"Interplay between extracellular matrix components and cellular and molecular mechanisms in kidney fibrosis","volume":"135","author":"Rayego-Mateos","year":"2021","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151692_bib0012","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1681\/ASN.2018121251","article-title":"Cellular senescence in the kidney","volume":"30","author":"Docherty","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151692_bib0013","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41581-024-00907-0","article-title":"Crosstalk between glomeruli and tubules","volume":"21","author":"Fogo","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2026.151692_bib0014","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2026.151692_bib0015","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"9176","key":"10.1016\/j.semnephrol.2026.151692_bib0016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semnephrol.2026.151692_bib0017","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2026.151692_bib0018","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151692_bib0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Int Med"},{"key":"10.1016\/j.semnephrol.2026.151692_bib0020","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151692_bib0021","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4S","key":"10.1016\/j.semnephrol.2026.151692_bib0022","first-page":"S117","article-title":"Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int (Suppl)"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151692_bib0023","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.13994","article-title":"Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk","volume":"22","author":"Schernthaner","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151692_bib0024","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.semnephrol.2026.151692_bib0025","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151692_bib0026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"10365","key":"10.1016\/j.semnephrol.2026.151692_bib0027","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151692_bib0028","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151692_bib0029","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167700","article-title":"Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors","volume":"133","author":"Tuttle","year":"2023","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151692_bib0030","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"10.1016\/j.semnephrol.2026.151692_bib0031","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151692_bib0032","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151692_bib0033","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151692_bib0034","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1681\/ASN.0000000823","article-title":"Effect of finerenone on morbidity and mortality in CKD","volume":"37","author":"Ostrominski","year":"2026","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151692_bib0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151692_bib0036","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151692_bib0037","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151692_bib0038","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.ajkd.2024.08.002","article-title":"Glucagon-like peptide-1 receptor agonists: new evidence of kidney and cardiovascular protection from the FLOW and SELECT trials","volume":"85","author":"Taal","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151692_bib0039","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151692_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151692_bib0041","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"10184","key":"10.1016\/j.semnephrol.2026.151692_bib0042","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"issue":"10417","key":"10.1016\/j.semnephrol.2026.151692_bib0043","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.semnephrol.2026.151692_bib0044","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"issue":"10416","key":"10.1016\/j.semnephrol.2026.151692_bib0045","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151692_bib0046","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2024.12.011","article-title":"Soluble guanylate cyclase as a direct target for pharmacologic mitigation of chronic kidney disease","volume":"107","author":"Jensen","year":"2025","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.semnephrol.2026.151692_bib0047","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","article-title":"Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151692_bib0048","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","article-title":"The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"40","author":"Gansevoort","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151692_bib0049","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.08410520","article-title":"Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial","volume":"16","author":"Hanrahan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151692_bib0050","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"14","key":"10.1016\/j.semnephrol.2026.151692_bib0051","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151692_bib0052","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"issue":"10424","key":"10.1016\/j.semnephrol.2026.151692_bib0053","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151692_bib0054","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/MNH.0000000000000830","article-title":"Defining improvement in chronic kidney disease: regression and remission","volume":"31","author":"Taal","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:44:35Z","timestamp":1791924275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929526000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0270929526000288"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151692","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151692"}}